Compare JPMorgan Chase & Co (JPM) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Nuwellis Inc — how do they compare? JPMorgan Chase & Co trades at $344.68 (market cap $900.78B), while Nuwellis Inc trades at $2.9 (market cap $1.09M). The key difference: JPMorgan Chase & Co is far larger — about 826403.7× Nuwellis Inc's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| JPM | NUWE | |
|---|---|---|
Market Cap | $900.78B | $1.09M |
Volume | 10,479,943 | — |
Sector | Financials | Technology |
52-Week High | $346.91 | $527.46 |
52-Week Low | $282.84 | $2.80 |
Dividend Yield | 1.77% | — |
Enterprise Value | — | -$722.58K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $345.10, up 1.17% on the day, with strong technical momentum as the stock approaches resistance at $347. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026, with revenue growing to $181.85 billion in 2025. Analyst sentiment remains positive with a consensus price target of $372.73, representing 8% upside potential from current levels.
JPMorgan demonstrates solid fundamentals with a reasonable P/E of 14.52 and strong net income margin of 33.4%. However, negative operating cash flow of -$147.78 billion in 2025 and geopolitical risks highlighted by CEO Jamie Dimon present headwinds. The stock offers value for long-term investors but faces near-term volatility from earnings uncertainty and macroeconomic concerns.
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
